Greg Harrison
Stock Analyst at Scotiabank
(2.22)
# 2,500
Out of 4,829 analysts
86
Total ratings
43.94%
Success rate
-4.81%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $28 → $20 | $17.46 | +14.55% | 4 | May 8, 2025 | |
| GERN Geron | Downgrades: Sector Perform | $4 → $1.5 | $1.28 | +17.19% | 3 | May 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $450 → $442 | $435.59 | +1.47% | 6 | May 6, 2025 | |
| LQDA Liquidia | Maintains: Sector Outperform | $34 → $36 | $15.66 | +129.89% | 6 | May 5, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $74 → $71 | $28.99 | +144.91% | 5 | May 2, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $52 → $55 | $35.45 | +55.15% | 6 | Apr 30, 2025 | |
| UTHR United Therapeutics | Upgrades: Neutral | $314 | $306.84 | +2.34% | 2 | Apr 21, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $21.12 | +46.78% | 9 | Apr 1, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $338 → $342 | $263.13 | +29.97% | 5 | Mar 31, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Sector Outperform | $40 | $18.23 | +119.42% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $51 → $52 | $7.17 | +625.24% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $45.33 | +65.45% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $44 → $41 | $13.55 | +202.58% | 5 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $60 | $22.66 | +164.84% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $5.87 | +206.91% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $22 | $7.38 | +198.10% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $13 → $15 | $1.58 | +849.37% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $8.73 | +942.38% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $9.75 | +23.08% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.73 | +104.58% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $14.61 | +166.94% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $4.47 | -32.89% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $3.25 | +2,053.85% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $29.39 | -72.78% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $19.93 | +170.95% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 → $6 | $0.68 | +783.52% | 5 | Mar 14, 2022 |
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $17.46
Upside: +14.55%
Geron
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.28
Upside: +17.19%
Vertex Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $450 → $442
Current: $435.59
Upside: +1.47%
Liquidia
May 5, 2025
Maintains: Sector Outperform
Price Target: $34 → $36
Current: $15.66
Upside: +129.89%
Agios Pharmaceuticals
May 2, 2025
Maintains: Sector Outperform
Price Target: $74 → $71
Current: $28.99
Upside: +144.91%
BridgeBio Pharma
Apr 30, 2025
Maintains: Sector Outperform
Price Target: $52 → $55
Current: $35.45
Upside: +55.15%
United Therapeutics
Apr 21, 2025
Upgrades: Neutral
Price Target: $314
Current: $306.84
Upside: +2.34%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $21.12
Upside: +46.78%
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Sector Outperform
Price Target: $338 → $342
Current: $263.13
Upside: +29.97%
Beam Therapeutics
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $18.23
Upside: +119.42%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $51 → $52
Current: $7.17
Upside: +625.24%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $45.33
Upside: +65.45%
Jan 16, 2025
Maintains: Sector Outperform
Price Target: $44 → $41
Current: $13.55
Upside: +202.58%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $60
Current: $22.66
Upside: +164.84%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $5.87
Upside: +206.91%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $22
Current: $7.38
Upside: +198.10%
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $1.58
Upside: +849.37%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $8.73
Upside: +942.38%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $9.75
Upside: +23.08%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.73
Upside: +104.58%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $14.61
Upside: +166.94%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $4.47
Upside: -32.89%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $3.25
Upside: +2,053.85%
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $29.39
Upside: -72.78%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $19.93
Upside: +170.95%
Mar 14, 2022
Downgrades: Underperform
Price Target: $18 → $6
Current: $0.68
Upside: +783.52%